WO2000038620A2 - A composition useful to treat periodontal disease - Google Patents
A composition useful to treat periodontal diseaseInfo
- Publication number
- WO2000038620A2 WO2000038620A2 PCT/CA1999/001243 CA9901243W WO0038620A2 WO 2000038620 A2 WO2000038620 A2 WO 2000038620A2 CA 9901243 W CA9901243 W CA 9901243W WO 0038620 A2 WO0038620 A2 WO 0038620A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- resveratrol
- tcdd
- periodontal disease
- gum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Definitions
- the present invention relates to a composition useful to treat periodontal disease.
- the present invention relates to a composition comprising resveratrol, and its use to treat periodontal disease. It is particularly useful in the treatment of individuals at high risk for developing periodontal disease, for example, those exposed to high levels of aryl hydrocarbons such as individuals that smoke tobacco products, individuals exposed to second-hand tobacco smoke and individuals exposed to environmental pollutant AhR ligands.
- Periodontal disease is characterized by gingival inflammation, bone loss and loss of teeth. It is believed to be the most common cause of tooth loss resulting in significant dental morbidity. Smokers are 2.5-6 times more likely to develop periodontal disease than non-smokers, and there is evidence for a direct correlation between the number of cigarettes smoked and the risk of developing the disease (Barbour et al, 1977, Crit Rev Oral Biol Med 8(4): 437-60). Smokers also tend to exhibit increased severity of periodontal disease compared to non-smokers with direct correlations between smoking and increased attachment loss, increased pocket depth, and reduced bone crest height (Barbour et al, supra).
- Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF- ⁇ ) and interleukin 1 ⁇ (IL-1 ⁇ ) possess bone-resorptive properties, and are generally considered to play a role in the pathogenesis of periodontal disease (Hou et al, 1995, J Clin Periodontol 22(2): 162-7.; Liu et al, 1996, Cvtokine 8(2): 161-7; Galbraith et al, 1997, J Periodontol 68(9): 832-8).
- Pathogenic oral bacteria have been shown to cleave active IL-l ⁇ from pro-IL-l ⁇ (Beausejour et al, 1997, Infect Immun 65(8): 3199-202).
- Blocking antibodies which inhibit IL-l/TNF, reduce both inflammatory cell recruitment and bone loss in patients with periodontal disease (Assuma et al, 1998, J Immunol 160(1): 403-9).
- AhR aryl hydrocarbon receptor
- Resveratrol the parent compound of a family of molecules including glucosides and polymers, is a potent AhR antagonist as described in French Patent Application No. 9805673 filed May 5, 1998. It is an anti-fungal agent or phytoalexin produced by plants classified as spermatophytes of which vines, peanuts and pines are prime representatives (Soleas et al., 1997, Clin Biochemistry, 30:91-113).
- resveratrol As an AhR antagonist, resveratrol, the chemical name of which is 3,5,4'-trihydroxystilbene, is useful generally to prevent the toxic effects of environmental exposure to AhR ligands, including, for example, halogenated and polycyclic aryl hydrocarbons, polyaromatic hydrocarbons and polychlorinated biphenyls.
- AhR ligands including, for example, halogenated and polycyclic aryl hydrocarbons, polyaromatic hydrocarbons and polychlorinated biphenyls.
- resveratrol has been demonstrated to prevent the induction of the proinflammatory cytokine, IL-1 Beta, by AhR ligands (Casper et al. 1999. Molecular Pharmacology, 56:784-790).
- the present invention provides a composition for treating periodontal disease comprising resveratrol and a pharmaceutically acceptable carrier.
- a method for treating periodontal disease in a patient comprising the step of administering a composition comprising resveratrol as described to the oral cavity of the patient.
- an article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein the composition comprises resveratrol in combination with at least one pharmaceutically acceptable carrier and is effective to treat periodontal disease, and the packaging material comprises a label which indicates that the composition is for use to treat periodontal disease.
- Other aspects of the invention include the use of resveratrol for treating periodontal disease and for the manufacture of pharmaceutical compositions for treating periodontal disease.
- Figures 1 A-D illustrate a histological evaluation of 5 ⁇ m thick paraffin- embedded sections obtained from chick periosteal osteogenesis (CPO) cultures including control (A), TCDD-treated (B), resveratrol-treated (C) and TCDD- and resveratrol- treated cultures (D);
- Figures 2A-C are bar graphs illustrating the effects of TCDD, reservatrol, and TCDD combined with resveratrol on APA in the CPO model;
- Figure 3 illustrates the agarose gel electrophoresis patterns for mRNA bands of the bone proteins, AP (alkaline phosphatase), BSP (bone sialoprotein), collagen type I and OPN (osteopontin) in CPO control cultures (C), cultures treated with TCDD (T), cultures treated with resveratrol (R) and cultures treated with TCDD and resveratrol (T +R);
- C CPO control cultures
- T cultures treated with TCDD
- R resveratrol
- T +R cultures treated with TCDD and resveratrol
- Figure 4 is a bar graph illustrating the effect of resveratrol (R), TCDD (T) and resveratrol combined with TCDD (TR) on mRNA levels of the bone proteins, AP, BSP, collagen and OPN in the CPO model;
- Figure 5 is a bar graph illustrating the effect of TCDD, resveratrol and
- FIG. 6 illustrates the effect of various TCDD concentrations in the presence of increasing amounts of resveratrol on AP levels in the rat SBMC (stromal bone marrow cell) model
- Figure 7 illustrates the effect of various TCDD concentrations in the presence of increasing amounts of resveratrol on mineralization levels in the rat SBMC line;
- Figures 8A-B are graphs showing the results of live cell (SBMC) competitive uptake/binding assays between radiolabelled TCDD and unlabelled TCDD (A) and between radiolabelled TCDD and unlabelled resveratrol;
- Figure 9 is a bar graph illustrating the effect of TCDD on APA in rat bone marrow cells in the presence of resveratrol added either simultaneously with the TCDD or separately over days 4-10 of the culture;
- Figure 10 is a bar graph as in Fig. 3 in which resveratrol is added either simultaneously with the TCDD or separately over days 10-16 of the culture; and Figures 11 A-E are a series of graphs illustrating the effects of increasing concentrations of resveratrol on APA activity in the presence of concentrations of TCDD which decrease in graphs A to E.
- Figures 11 A-E are a series of graphs illustrating the effects of increasing concentrations of resveratrol on APA activity in the presence of concentrations of TCDD which decrease in graphs A to E.
- a novel composition to treat periodontal disease comprising resveratrol and a pharmaceutically acceptable carrier.
- periodontal disease as it is used herein with respect to periodontal disease is meant to encompass both treatment of existing periodontal disease as well as prevention of anticipated periodontal disease.
- prevention and treatment of periodontal disease in accordance with the present invention refers to the inhibition of, or at least the reduction of, inflammation, bone loss and/or attachment loss associated with periodontal disease.
- the present composition comprises resveratrol.
- resveratrol is meant to encompass not only the parent compound, i.e. 3,5,4'-trihydroxystilbene, but also derivatives of resveratrol which are aryl hydrocarbon receptor (AhR) antagonists.
- AhR aryl hydrocarbon receptor
- resveratrol derivatives which are AhR antagonists include, but are not limited to, piceatannol (3,4,3', 5'-tetrahydroxystilbene), oxyresveratrol (2,3',4,5'-tetrahydroxystilbene), 4,4'-dihydroxystilbene, and the alpha- and beta-glucoside, galactoside and mannoside derivatives thereof, such as piceid.
- the present composition comprises resveratrol together with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means acceptable for use in the pharmaceutical and veterinary arts, i.e. a carrier which is non-toxic and which does not adversely affect the activity of resveratrol to treat periodontal disease.
- Pharmaceutically acceptable carriers useful to prepare the present composition for administration include conventional carriers used in formulating alcohol-soluble drugs, such as diluents, excipientsand the like. Reference may be made to "Remington's Pharmaceutical Sciences", 17th Ed., Mack Publishing Company, Easton, Perm., 1985, for guidance on drug formulations generally. As will be appreciated, the pharmaceutical carriers used to prepare compositions in accordance with the present invention will depend on the desired administrable form.
- the most appropriate administrable form of the present composition is a topical dosage form that can be applied to affected areas of the oral cavity.
- Appropriate topical dosage forms include pastes, gels, rinses, sprays (aerosol or other), powders for reconstitution, tablets and gums.
- the carrier and other components of the composition will vary with the selected administrable dosage form.
- the resveratrol may first be admixed with an appropriate alcohol, i.e. an alcohol that is suitable for administration to the oral cavity of a patient and non-toxic at the dosage administered.
- an appropriate alcohol is, for example, ethyl alcohol, in an amount ranging from about 5% to about 30% by weight of the composition.
- the active ingredient(s) is admixed with an amount of alcohol of about 27% by weight of the total composition.
- the resveratrol solution may be admixed with further additives, as will be more fully described, in order to be suitable for administration.
- the resveratrol For the preparation of the present composition into a dosage form other than a solution, i.e. a paste, gel, powder or gum, the resveratrol must first be micronized, using conventional physical procedures well known in the art, prior to being admixed with appropriate carriers.
- micronized resveratrol is combined with carriers conventionally used to formulate a paste, including thickening agents such as methylcellulose or hydroxypropyl methylcellulose, humectants and surfactants, as described in more detail in EP 568 160 and U.S. 5,496,541 , the contents of which are incorporated herein by reference.
- micronized resveratrol may be admixed with gel carriers such as gelatin, polyethylene glycol, guar gum or combinations thereof.
- gel carriers such as gelatin, polyethylene glycol, guar gum or combinations thereof.
- Structurant compounds are also normally present in a gel, examples of which include polyoxyethylene-polyoxypropylenecopolymers.
- Such structurants are generally present in amounts ranging from about 18 to about 25% by weight of the composition.
- Toothpaste or gel forms of the present composition may further comprise an abrasive.
- suitable abrasives include water-insoluble alkali or alkaline earth metal salts of metaphosphate, calcium carbonate, aluminate and silicate.
- the amount of such abrasive generally contained in a toothpaste or gel ranges from about 5 to about 80% by weight of the composition.
- micronized resveratrol may be combined with conventionally used carriers including one or more natural or synthetic elastomers, optionally supplemented with one or more solvents, plasticizers or fillers.
- Natural elastomers suitable for use include substances of vegetable origin such as chicle, jelutong, gutta percha, guayule and crown gum.
- Examples of synthetic elastomers include butadiene-styrene copolymers, isobutylene-isoprenecopolymers, polyethylene, polyisobutylene, poly vinylacetate and combinations thereof.
- the elastomer generally comprises from about 14% to about 50% by weight of the composition.
- Solvent may additionally be added to soften the elastomer component.
- Suitable solvents include methyl, glycerol or pentaerythritol esters of rosins or modified rosins, such as hydrogenated, dimerized or polymerized rosins as well as terpene resins such as polyterpene.
- Specific examples of such solvents include pentaerythritol ester of wood rosin, glycerol ester of partially dimerized or polymerized rosin, glycerol ester of tall oil rosin or wood rosin, and partially hydrogenated methyl ester of rosin.
- Such solvents may be used in an amount ranging from about 10% to about 75% of the composition.
- Resveratrol may be dissolved in such solvents or micronized and suspended in the solvent or elastomer phase of the preparation.
- Plasticizers, softeners or emulsifiers may also be included in the gum composition in an amount of up to about 30% by weight of the composition. Examples of these components include lanolin, lecithin, glyceryl monostearate, stearic acid, sodium stearate, postassium stearate, glyceryl triacetate, triacetin and glycerin, as well as natural waxes, petroleum waxes, paraffin waxes and microcrystalline waxes to improve texture and consistency.
- the present composition may also be formulated to include one or more additional active ingredients provided that any such additional active ingredient or ingredients do not impact adversely on the activity of the composition to treat periodontal disease.
- Additional active ingredients may include, for example, fluoride compounds such as sodium fluoride, potassium fluoride, calcium fluoride, mangnesium fluoride, stannous fluoride, stannous monofluorophosphate, sodium monofluorophosphateand copper fluoride; anti-bacterial agents such as chlorhexidine,triclosan, sanguinarine and cetylpyridinium salts; antitartar agents such as tetrapotassiumor tetrasodiumpyrophosphates; anti-inflammatory agents such as ketoprofen and benzymidine; de-odourizers; stain removers; and other ingredients that would be well-known by those of skill in the art.
- flavouring agents based on oils of spearmint and peppermint may be added to the composition to provide a desirable tasting composition.
- Other compounds which may be used to provide a composition with an appealing flavour include menthol, clove, wintergreen eucalyptus and aniseed.
- An amount of flavouring agent suitable for inclusion in the present composition may be in the range of about 0.1 to about 5 % by weight of the total composition.
- Sweetening agents may also be added to the present composition. Examples of suitable sweetening agents include, but are not to be limited to, saccharin, sodium cyclamate, aspartame, xylitol and sucrose.
- Sweetening agents generally comprise about 0.1 to about 5% by weight of the total composition.
- Colorant such as titanium dioxide, antioxidants such as ascorbic acid or alpha-tocopherol, buffer to retain the pH at an acceptable value including as an example potassium phosphate, preservative such as potassium sorbate or calcium propionate, silicone and other synthetic or natural polymers may also be added to the present composition in amounts that would not have an adverse effect on the activity of the composition as would be appreciated by one of skill in the art.
- additives that may be added to the present composition, reference may be made to U.S. 5,496,541, U.S. 5,585,110, U.S. 5,298,237 and U.S.
- a therapeutically effective amount of the present composition is administered to the oral cavity of the individual for a suitable period of time.
- therapeutically effective amount means an amount of resveratrol sufficient to treat periodontal disease without causing intolerable side effects.
- Precise dosages of the composition appropriate for use to treat an individual are established in appropriately controlled clinical trials. As will be appreciated, the appropriate dosage of the present composition will vary with the administrable form of the composition.
- an effective treatment regimen will involve the administrationof a dosage in the range of at least about 1 mg/g up to about 20 mg/g of paste or gel, or up to an amount of resveratrol which is capable of being absorbed by the paste or gel while still being cost effective; a range of at least about 0.2 mg/stick of gum up to about 200 mg/stick of gum, or up to an amount of resveratrol which is capable of being absorbed by the gum carriers while still being cost effective; and a range of about 0.001 - 5 g/litre of liquid rinse or spray, a preferred dosage of which being represented by about 0.02 g of resveratrol/litre.
- the present composition in order to be effective in treating periodontal disease, the present composition must be in contact with affected areas of the oral cavity for an acceptable period of time per use, and must be used at least 1 to 3 times daily.
- the treatment time will vary with the administrable form of the composition.
- the composition in the form of a rinse, the compositionis preferably used for 30-60 seconds per use, 2-3 times daily; in the form of a gel or paste, the compositionis preferably used for about 1-2 minutes, 2-3 times daily; and in the form of a gum, the composition can be used for a longer period of time than other dosage forms, generally for at least several minutes per stick of gum.
- the present invention provides in another of its aspects an article of manufacture which includes packaging material contained within which is a pharmaceutically acceptable resveratrol composition that is effective to treat periodontal disease.
- the packaging material comprises a label which indicates that the composition can be used to treat periodontal disease.
- CPO chick periosteal osteogenesis
- the folded explant was then placed on a Millipore filter (HA 0.45 ⁇ m), which was transferred onto a stainless steel grid resting in the center well of an organ culture dish (Falcon Plastics, Lincoln Park, NJ, USA) that was filled with culture media to a level such that the culture was supported at the gas-liquid interface ( ⁇ 1.5ml of media).
- HA 0.45 ⁇ m a Millipore filter
- Three cultures were placed in each dish which was then covered and incubated at 37°C in a humidified atmosphere containing 5% C0 2 in air.
- BGJ b medium Fitton- Jackson Modification
- L-glutamine Gibco, Grand Island, NY, USA
- antibiotic 10,000 units/ml Penicillin G sodium, 10,000 ⁇ g/ml Streptomycin sulfate in 0.85% saline
- fetal calf serum Gibco
- 10 "7 M dexamethasone Sigma, St. Louis, MO, USA
- lOmM ⁇ -glycerophosphate 300 ⁇ g/ml L-ascorbate
- the compounds were administered over four different temporal phases, as outlined below in the time-line diagram: a) days 0-6; b) days 0-2; c) days 2-4 or d) days 4-6 (Note: all cultures were stopped at 6 days). Results were compared to e) vehicle alone over days 0-6.
- pN-p paranitrophenol-phosphate
- RNA isolation of total RNA from periosteal cultures to determine affect of TCDD on message levels of bone proteins was accomplished using the QIAGEN Rneasy ® kit and QIAShredder ® (Hilden, Germany) according to the manufacturer's instructions.
- Total RNA (2 ⁇ g) was reverse transcribed using Superscript IITM RNase H " Reverse Transcriptase (Gibco BRL, City Country).
- PCR reactions were performed in 2 ⁇ l reactions at a cycle number ensuring a linear amplification profile (BSP, 5 min at 94°C, 30 cycles [of 20 sec at 94°C, 20 sec at 55°C, 20 sec at 72°C]; Collagen 5 min at 94°C, 30 cycles [of 20 sec 94°C, 20 sec 58°C, 20 sec 72°C]; AP 5 min at 94°C, 30 cycles [of 20 sec 94°C, 20 sec 59°C, 20 sec 72°C]; OPN 5 min at 85°C, 5 min at 94°C, 25 cycles [20 sec at 94°C, 20 sec at 60°C, 20 sec at 72°C] 7 min at 72°C).
- BSP linear amplification profile
- oligonucleotides for BSP sense: 5'- GAGCGGGCACCGGTACTA-3'; antisense: 5'- CTCTAGACACTGACATCCTGCTC-3'
- AP sense: 5'- ACCGCTGCAACACCACCA-3'; antisense: 5'- TCCCCGCAGGCTTAGTGT- 3'
- Collagen sense: 5'-ACCCGACCCTAAGACAAA-3'; antisense: 5'-
- TCGGCGTTGGGGCAGT-3' OPN (sense 5'-AGGCCGGGGTGACAGTGT- 3'; antisense 5'-CCCCGCAGGCAGCACTC-3') were synthesized by Life Technologies (Gibco BRL, Rockville, MD).
- PCR products were electrophoresed on 1.5 (wt/vol)% agarose gels with O.l ⁇ g/ml ethidium bromide. The gels were visualized on an UV transilluminator and photographed using 667 Polaroid film. The inverse images of the photographs were analyzed by densitometry. All values were normalized for the internal control, ⁇ -actin.
- Radiolabeled collagen was measured in CPO cultures incubated with I4 C- glycine (Amersham, 59mCi/mMole) at a concentration of lO ⁇ ci/ml media in each group over days 4-6.
- the cultures were hydrolyzed in 0.1 ml of 0.1N HCl and vortexed. After 15 minutes, the supernatant was removed and saved in a 2ml eppendorf tube.
- the culture was transferred to a 0.5ml eppendorf tube containing 0.1ml of pepsin (50 ⁇ g/ml in 0.1% glacial acetic acid) for further digestion of labeled collagen. These were maintained in a 15°C water bath for 5 hours, vortexing the samples every hour.
- the supernatant was transferred to a new 0.5ml eppendorf tube and was then lyophilized overnight.
- the amount of radiolabeled collagen was determined by gel electrophoresis as described hereunder.
- the lyophilized samples were reconstituted with 0.1ml of a solution made of 70% sample buffer (lOmM Tris»HCl and ImM EDTA, pH 8.0) (Sigma- Aldrich Canada Ltd., Oakville, Canada), 2.5% SDS (Sigma), 5% ⁇ -mercaptoethanol (Sigma) and 0.01% bromophenol-blue (Sigma).
- the samples were boiled for 5 minutes and were loaded on a 7.5% homogenous SDS gel (Amersham Pharmacia Biotech, Inc, Quebec).
- the gel was then run on the PhastSystemTM (Pharmacia, Quebec) at 250V, 10.0mA, 3.0W, 15°C for 20 minutes.
- Fluorography was used to analyze the amount of newly synthesized R elabeled collagen in each sample.
- Each gel was coated with 20% PPO in DMSO.
- the gels were then exposed to photographic film (Kodak, Rochester, NY, USA) for 2 days at -80°C, and the film then developed.
- the intensity of the resultant bands on the film was quantified using a laser densitometer to give a measure of the amount of newly synthesized collagen in each sample.
- Newly synthesized collagen type I levels (reported as Absorbance Units (AU) x mm) were decreased by about 30% in the treatment groups receiving 10 "9 M TCDD alone (p>0.05), while 10 "6 M resveratrol alone had no effect compared to vehicle (Fig. 5).
- Co-treatment with TCDD and resveratrol increased the newly synthesized collagen type I level (Fig. 5a), but this was not significantly different from the collagen levels shown for cultures treated with TCDD alone.
- Figs. 5a As shown in Figs.
- mRNA levels for type I collagen were reduced significantly (50%, p ⁇ 0.05) in the presence of TCDD in comparison to control while cultures treated with both TCDD and resveratrol had identical levels of mRNA for Type I collagen.
- Cells for the rat SBMC model were obtained from Dr. Sandu Pitaru (Tel Aviv University, Israel) and maintained in T 25 tissue culture flasks (Sarstedt, Newton, NC, USA) in a medium composed of ⁇ MEM+RNA+DNA+antibiotic supplemented with 10% fetal calf serum, lOmM ⁇ -glycerophosphate, 10 "8 M dexamethasone, 50 ⁇ g/ml vitamin C and 3ng/ml fibroblast growth factor. The media were changed every 48 hours and the cells subcultured when almost confluent (approximately every 72hrs). Cells were grown for a period of 1-2 weeks to allow for formation of mineralized bone nodules.
- SBMC cultures were assayed for AP activity using paranitrophenol- phosphate (pN-p) as the substrate as described above for CPO cultures.
- AP activity was also measured using direct staining of SBMC cultures in 96 well plates as described previously (Tenenbaum et al., Anat Rec. 1995. 242(2):200-10). Mineralization in the SBMC cultures was determined using
- cytosol preparations are generally obtained from whole organs. Therefore, whereas mass cultures of cells would be required to obtain usable amounts of cytosol, we chose to rely on vital cell uptake studies despite the fact that "classic" competition/binding curves are not necessarily attainable with this approach. The need for preincubation (see below) may also alter competition kinetics in this type of binding assay.
- Cells were plated at a density of 10,000 per well in Titertek 96-well plates, and left overnight to attach in medium. The medium was removed by aspiration and the various concentrations of cold drug (TCDD, resveratrol) were prepared and added to the wells in a volume of 90 ⁇ l.
- TCDD cold drug
- TCDD (3.3xlO "9 M and higher) induced a 33% reduction in AP activity versus control but this reduction was not reversed by administration of resveratrol at various concentrations.
- a 33% reduction in AP activity was also shown following treatment with a lower concentration of TCDD (l.lxlO "9 M).
- increasing concentrations of resveratrol (4xlO "8 M to lxl0 "5 M) abrogated the effects of TCDD and brought AP activity back to, and even above that seen in control cultures. This pattern was repeated in the cultures receiving lower levels of TCDD.
- Rat bone marrow cells were derived from femoral bones removed from adult male Wistar rats as described previously (Maniatopoulos et al., Cell Tissue Res, 1988, 254(2):317-330). These cells, grown in the presence of dexamethasone, vitamin C and b-glycerophosphate, differentiated into osteoblasts as shown by increases in APA and the production of mineralized bone nodules within 12-14 days. For the purposes of this investigation, we analyzed 10-16 day cultures for APA, as this was a reliable marker for osteoblastic differentiation in this system.
- TCDD when added to the cells at a concentration of 10 "9 M in alcohol, inhibited osteodifferentiation compared to an alcohol-treated control, as measured by APA, by about 50% while resveratrol alone had no significant effects.
- Resveratrol at a concentration of 10 "6 molar in alcohol, completely abrogated the effects of TCDD when both agents were added together or singly between days 4- 10 ( Figure 9). Similar results were observed when RBMC cultures were exposed to TCDD and resveratrol over days 10-16 ( Figure 10).
- Example 4 The Effects of Resveratrol on Dioxin-Mediated Inhibition of Bone Cell Differentiation in a Rat Bone Marrow Cell Line (RBMCL)
- resveratrol was able to inhibit TCDD effects on osteoblastic differentiation in the RBMCL as assessed by APA.
- TCDD TCDD-mediated inhibition of osteoblastic differentiation
- aryl hydrocarbon receptor ligands appear to have a profound inhibitory effect on osteogenic cell differentiation and mineralised bone formation in a variety of systems.
- these negative effects are either partially or completely abrogated by resveratrol depending on the relative doses of either agent used as well as the model systems used for testing.
- the effects of resveratrol are highly consistent with a receptor- mediated phenomenon. That these effects are demonstrated in different model systems and even in different species, supports the notion that these effects will be replicated in human model systems both in vitro and in vivo.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69913380T DE69913380T2 (en) | 1998-12-24 | 1999-12-23 | COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES |
US09/868,451 US6716883B1 (en) | 1998-12-24 | 1999-12-23 | Composition useful to treat periodontal disease |
EP99962021A EP1140050B1 (en) | 1998-12-24 | 1999-12-23 | A composition useful to treat periodontal disease |
AU18530/00A AU1853000A (en) | 1998-12-24 | 1999-12-23 | A composition useful to treat periodontal disease |
CA2350396A CA2350396C (en) | 1998-12-24 | 1999-12-23 | A composition useful to treat periodontal disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11393798P | 1998-12-24 | 1998-12-24 | |
US60/113,937 | 1998-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000038620A2 true WO2000038620A2 (en) | 2000-07-06 |
WO2000038620A3 WO2000038620A3 (en) | 2000-10-19 |
Family
ID=22352409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/001243 WO2000038620A2 (en) | 1998-12-24 | 1999-12-23 | A composition useful to treat periodontal disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1140050B1 (en) |
AU (1) | AU1853000A (en) |
CA (1) | CA2350396C (en) |
DE (1) | DE69913380T2 (en) |
WO (1) | WO2000038620A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1138323A2 (en) * | 2000-03-24 | 2001-10-04 | D.B.P. (Development Biotechnological Processes) di Rossi Valentina e C. s.n.c. | Resveratrol for the treatment of exfoliative eczema, acne or psoriasis |
WO2002032410A2 (en) * | 2000-10-19 | 2002-04-25 | Imperial College Innovations Limited | Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
WO2006127987A2 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
US7163961B1 (en) * | 1999-01-29 | 2007-01-16 | Sunstar Inc. | Drugs, foods and oral compositions containing stilbene-type compounds |
WO2007104867A2 (en) * | 2006-03-16 | 2007-09-20 | Af Consulting | Cosmetic, pharmaceutical, food and veterinary compositions whose activating action on genes of sirtuin type makes it possible to delay ageing in mammals and the harmful effects thereof |
WO2010062835A1 (en) * | 2008-11-26 | 2010-06-03 | Perio Sciences, Llc | Antioxidant compositions for soft oral tissue and methods of formulation and use there |
WO2010100197A1 (en) * | 2009-03-03 | 2010-09-10 | Agetis Supplements | Resveratrol compositions for use as dietary supplements |
EP2231133A2 (en) * | 2008-01-08 | 2010-09-29 | David Rubin | Method and compositions for administering resveratrol and pterostilbene |
WO2013056298A1 (en) * | 2011-10-19 | 2013-04-25 | Nad Life Pty Ltd | Pharmaceutical compositions of resveratrol |
US9421180B2 (en) | 2011-09-30 | 2016-08-23 | Perio Sciences, Llc | Antioxidant compositions for treatment of inflammation or oxidative damage |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773020A2 (en) * | 1995-10-17 | 1997-05-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy |
WO1998033494A1 (en) * | 1997-02-04 | 1998-08-06 | Kosbab John V | Compositions and methods for prevention and treatment of vascular degenerative diseases |
FR2766176A1 (en) * | 1997-07-15 | 1999-01-22 | Caudalie | COMPOSITIONS BASED ON RESVERATROL DERIVATIVES |
FR2778337A1 (en) * | 1998-05-05 | 1999-11-12 | Inst Nat Sante Rech Med | ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS |
WO1999059561A2 (en) * | 1998-05-18 | 1999-11-25 | Hensley, Kenneth, L. | Resveratrol inhibition of myeloperoxidase |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753359A (en) * | 1993-06-11 | 1995-02-28 | Kao Corp | Lipoxygenase inhibitor |
CN1104896A (en) * | 1993-11-15 | 1995-07-12 | 陈文绍 | Multifunction medicine for curing trauma |
-
1999
- 1999-12-23 EP EP99962021A patent/EP1140050B1/en not_active Expired - Lifetime
- 1999-12-23 DE DE69913380T patent/DE69913380T2/en not_active Expired - Fee Related
- 1999-12-23 WO PCT/CA1999/001243 patent/WO2000038620A2/en active IP Right Grant
- 1999-12-23 CA CA2350396A patent/CA2350396C/en not_active Expired - Fee Related
- 1999-12-23 AU AU18530/00A patent/AU1853000A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773020A2 (en) * | 1995-10-17 | 1997-05-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy |
WO1998033494A1 (en) * | 1997-02-04 | 1998-08-06 | Kosbab John V | Compositions and methods for prevention and treatment of vascular degenerative diseases |
FR2766176A1 (en) * | 1997-07-15 | 1999-01-22 | Caudalie | COMPOSITIONS BASED ON RESVERATROL DERIVATIVES |
FR2778337A1 (en) * | 1998-05-05 | 1999-11-12 | Inst Nat Sante Rech Med | ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS |
WO1999059561A2 (en) * | 1998-05-18 | 1999-11-25 | Hensley, Kenneth, L. | Resveratrol inhibition of myeloperoxidase |
Non-Patent Citations (5)
Title |
---|
CIOLINO ET AL: "Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor" CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 58, no. 24, 15 December 1998 (1998-12-15), pages 5707-5712, XP002090260 ISSN: 0008-5472 * |
DATABASE WPI Week 199729 Derwent Publications Ltd., London, GB; AN 1997-311392 XP002140688 & CN 1 104 896 A (CHEN), 12 July 1995 (1995-07-12) * |
EPODOC abstract of CN1154850 (fang genfa), 23-07-1997 XP002140687 * |
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 07 053359 A (KAO CORP.), 28 February 1995 (1995-02-28) * |
SUBBARAMAIAH, KOTHA ET AL: "Resveratrol inhibits the expression of cyclooxygenase-2 in human mammary and oral epithelial cells." PHARMACEUTICAL BIOLOGY, (DEC., 1998) VOL. 36, NO. SUPPL., PP. 35-43. , XP000910993 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7163961B1 (en) * | 1999-01-29 | 2007-01-16 | Sunstar Inc. | Drugs, foods and oral compositions containing stilbene-type compounds |
EP1138323A2 (en) * | 2000-03-24 | 2001-10-04 | D.B.P. (Development Biotechnological Processes) di Rossi Valentina e C. s.n.c. | Resveratrol for the treatment of exfoliative eczema, acne or psoriasis |
EP1138323A3 (en) * | 2000-03-24 | 2001-10-24 | D.B.P. (Development Biotechnological Processes) di Rossi Valentina e C. s.n.c. | Resveratrol for the treatment of exfoliative eczema, acne or psoriasis |
WO2002032410A2 (en) * | 2000-10-19 | 2002-04-25 | Imperial College Innovations Limited | Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
WO2002032410A3 (en) * | 2000-10-19 | 2002-08-01 | Imp College Innovations Ltd | Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
WO2006127987A2 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
WO2006127987A3 (en) * | 2005-05-25 | 2008-04-17 | Sirtris Pharmaceuticals Inc | Treatment of eye disorders with sirtuin modulators |
FR2898493A1 (en) * | 2006-03-16 | 2007-09-21 | Af Consulting | COSMETIC, PHARMACEUTICAL, FOOD AND VETERINARY COMPOSITIONS WHOSE ACTION ACTIVATION OF SIRTUIN GENES ENABLES DELAYING THE AGING OF MAMMALS AND ITS NEGATIVE EFFECTS |
WO2007104867A3 (en) * | 2006-03-16 | 2007-11-15 | Af Consulting | Cosmetic, pharmaceutical, food and veterinary compositions whose activating action on genes of sirtuin type makes it possible to delay ageing in mammals and the harmful effects thereof |
WO2007104867A2 (en) * | 2006-03-16 | 2007-09-20 | Af Consulting | Cosmetic, pharmaceutical, food and veterinary compositions whose activating action on genes of sirtuin type makes it possible to delay ageing in mammals and the harmful effects thereof |
EP2231133A2 (en) * | 2008-01-08 | 2010-09-29 | David Rubin | Method and compositions for administering resveratrol and pterostilbene |
EP2231133A4 (en) * | 2008-01-08 | 2014-08-20 | David Rubin | Method and compositions for administering resveratrol and pterostilbene |
US9752110B2 (en) | 2008-01-08 | 2017-09-05 | Ysdr, Llc | Method and compositions of preserving wine |
WO2010062835A1 (en) * | 2008-11-26 | 2010-06-03 | Perio Sciences, Llc | Antioxidant compositions for soft oral tissue and methods of formulation and use there |
WO2010100197A1 (en) * | 2009-03-03 | 2010-09-10 | Agetis Supplements | Resveratrol compositions for use as dietary supplements |
US9421180B2 (en) | 2011-09-30 | 2016-08-23 | Perio Sciences, Llc | Antioxidant compositions for treatment of inflammation or oxidative damage |
US10918613B2 (en) | 2011-09-30 | 2021-02-16 | Perio Sciences, Llc | Antioxidant compositions for treatment of inflammation or oxidative damage |
WO2013056298A1 (en) * | 2011-10-19 | 2013-04-25 | Nad Life Pty Ltd | Pharmaceutical compositions of resveratrol |
Also Published As
Publication number | Publication date |
---|---|
CA2350396A1 (en) | 2000-07-06 |
DE69913380T2 (en) | 2004-08-05 |
WO2000038620A3 (en) | 2000-10-19 |
EP1140050B1 (en) | 2003-12-03 |
AU1853000A (en) | 2000-07-31 |
EP1140050A2 (en) | 2001-10-10 |
DE69913380D1 (en) | 2004-01-15 |
CA2350396C (en) | 2010-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6716883B1 (en) | Composition useful to treat periodontal disease | |
US20060264497A1 (en) | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | |
US20070110683A1 (en) | Oral care formulation | |
EP1140050B1 (en) | A composition useful to treat periodontal disease | |
BRPI0518866B1 (en) | Oral compositions and cosmetic methods for preventing plaque and tartar formation and for treating plaque and calculus on an oral surface of a mammalian subject. | |
Lif Holgerson et al. | Xylitol concentration in saliva and dental plaque after use of various xylitol-containing products | |
KR0176015B1 (en) | Composition for prevention and treatment of periodontal disorders | |
RU2414210C1 (en) | Medication for removal of tobacco resins and based on it composition | |
JP7413465B2 (en) | Composition for preventing or treating oral diseases | |
KR20160124007A (en) | Composition for preventing or treating inflammatory diseases or pain | |
CA2312505A1 (en) | Resveratrol compositions for topical use in the treatment of oral diseases and infections | |
KR101703269B1 (en) | Oral care composition comprising Magnolia officinalis extract and bicarbonate | |
KR20110001472A (en) | Oral care composition comprising the extract of centella asiatica and oral tissue astringent | |
Bozkurt et al. | The effects of three oral sprays on plaque and gingival inflammation | |
KR0179523B1 (en) | Dentifrice composition for gingivitis curing | |
EP2790653B1 (en) | Oral care composition | |
RU2777153C1 (en) | Composition for oral care for patients with metabolic disorders | |
KR101344803B1 (en) | Oral care composition comprising extract of machilus thunbergii and sequestering agent | |
KR20180055520A (en) | Composition for prevention or treatment of oral disease comprising neferine | |
KR20180047704A (en) | Composition for prevention or treatment of oral disease comprising Scutellaria baicalensis extract | |
WO2001074324A1 (en) | New formulations for the removal of dental plaque, tartar and dental stains | |
JP2023147254A (en) | Stomatitis onset inhibiting composition | |
AU2012350708B2 (en) | Novel composition | |
WO2023272404A1 (en) | Oral pharmaceutical composition for preventing and/or treating diseases of the soft and hard tissues surrounding the tooth in the oral cavity | |
CN114601760A (en) | Oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2350396 Country of ref document: CA Kind code of ref document: A Ref document number: 2350396 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868451 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999962021 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999962021 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999962021 Country of ref document: EP |